‘Huge breakthrough' as breast cancer pill approved for NHS
A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common form of advanced disease.
The drug, capivasertib (also known as Truqap), offers new hope for up to 3,000 women annually with hormone receptor (HR)-positive, HER2-negative breast cancer harbouring specific genetic mutations and exhibiting spread.
Capivasertib, developed by AstraZeneca, targets the AKT protein, a molecule known to fuel the multiplication of cancer cells.
By inhibiting AKT's action, the drug effectively slows or halts the progression of the disease. Clinical trials have demonstrated the drug's efficacy, revealing that when combined with the hormone therapy, fulvestrant, capivasertib extended the period before cancer advancement by an average of 4.2 months compared to patients receiving fulvestrant and a placebo.
This translates to an improvement from 3.1 months to 7.3 months before disease progression.
The Institute of Cancer Research, London (ICR), which has dedicated decades of research to this area, lauded the NHS decision as a significant step forward.
The new drug is suitable for patients' tumours with mutations or alterations in the PIK3CA, AKT1 or PTEN genes, which are found in approximately half of patients with this form of breast cancer.
Professor Nicholas Turner, from the ICR and the Royal Marsden NHS Foundation Trust, led a major trial into the drug.
He said: 'This positive Nice (National Institute for Health and Care Excellence) recommendation means that thousands of NHS patients with advanced breast cancer with these specific biomarkers can now receive this innovative targeted treatment to keep their cancer from progressing for longer.
'It's an immensely rewarding moment to see this drug provide patients with a treatment option and precious extra time with their families.
'It is now crucial that advanced breast cancer patients have their cancer tested to identify those who could benefit from this capivasertib combination.'
Professor Kristian Helin, chief executive of the ICR, said: 'This announcement is a triumph that will improve treatment for these patients with the most common type of advanced breast cancer.
'Around half of patients with this kind of breast cancer have mutations in one or more of the genes, and for these patients, capivasertib can halt disease progression.
'I'm delighted that access to the drug is being expanded to NHS patients in England and Wales who are in desperate need of better options.
'The approval is also a significant achievement for the ICR, and a great success story for British science.
'Decades of discovery science work and a major drug discovery project by ICR researchers, along with a crucial partnership with Astex Pharmaceuticals, paved the way to the discovery of capivasertib by AstraZeneca.'
Professor Paul Workman, former chief executive of the ICR and researcher in the AKT drug discovery project, has previously said the drug is a 'huge breakthrough'.
He said of the Nice approval: 'I am delighted to celebrate this landmark moment and see capivasertib become available on the NHS.
'The drug's discovery and development, following early fundamental research, has been a long scientific journey for myself and the outstanding teams of scientists at the ICR, Astex and AstraZeneca.
'It's immensely gratifying that years of collaboration have contributed to this new cancer drug, which has the potential to improve the lives of so many NHS patients living with advanced breast cancer.'
Main symptoms of breast cancer in women
NHS
Claire Rowney, chief executive of Breast Cancer Now, welcomed the approval but said an initial rejection by Nice over uncertainties in the evidence had led to delays.
'This happens too often and urgent action must be taken to ensure the quick approval of breast cancer drugs so they can be made available promptly to those who need them,' she said.
'NHS England must now put in place prompt genetic testing to ensure those eligible receive capivasertib without further delay.
'The Scottish Medicines Consortium must also consider this treatment at pace now, so that we see it made available to all who need it across the UK.'
Professor Peter Johnson, national clinical director for Cancer at NHS England, said the treatment would not be suitable for everyone but giving patients more time 'before more intensive therapies are required is an important part of our drive to personalise cancer care and improve quality of life for patients wherever possible'.
Helen Knight, director of medicines evaluation at Nice, said it had heard about the 'devastating impact that being diagnosed with advanced breast cancer has on people's lives'.
She said Nice was 'pleased the company has worked with us so that we are able to recommend this promising new treatment as a good use of NHS resources and value for money for taxpayers.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Belfast Telegraph
40 minutes ago
- Belfast Telegraph
Midwife struck off after claiming vaccines ‘attacked babies' on social media
Seana Mary Kerr, of Newry, Northern Ireland, also told a pregnant woman in a shop that she should not be wearing a face mask during the Covid-19 pandemic, according to a Nursing and Midwifery Council (NMC) tribunal panel judgment. Ms Kerr, who had been a registered midwife since 2007, was found by a panel to have placed the woman at 'significant risk of harm' with her views, while she had 'risked seriously undermining the public confidence' in her profession at a crucial time with her posts. In the first of three social media posts in September 2020, Ms Kerr said that babies were being attacked in the womb through vaccination of mothers during pregnancy. Then, in March 2021, she claimed healthcare professionals were being 'complicit' in the national response to Covid-19, and that the health crisis was 'a Trojan horse intend[ed] to introduce a new era for humanity'. A further post in December that year made reference to how a group of people, described as 'they', had been 'planting the seeds' about Covid-19 over Christmas 2020 by referring to 'some bat in China'. Ms Kerr's advice and social media comments were given when she had identified herself as a midwife and was 'promoting her opinion on matters of clinical importance', the panel found. 'The panel considered that the actions of Ms Kerr took place during an exceptionally unusual time, where the entirety of the NHS was mobilised to protect the public from the international Covid-19 pandemic,' they said. 'Therefore, by expressing the view that other healthcare professionals, who Ms Kerr was working with in the Trust, were acting in ways which may cause harm, a view Ms Kerr held which was against the recognised guidance at the time, Ms Kerr risked seriously undermining the public confidence in the profession. 'It further noted that by making these accusations that Ms Kerr's colleagues may have suffered harm while working in an unprecedented and challenging situation.' The midwife approached the pregnant woman in the shop, which was her place of work, during the other allegation in question in August 2020. She identified herself as a midwife before advising the woman that she should not be wearing the face mask as it reduced the amount of oxygen her baby was receiving. Ms Kerr went on to tell the woman that she should not receive a flu vaccination as this would increase the risk of her baby being stillborn. The panel found the pregnant woman and her family were caused 'significant emotional harm' as a result of Ms Kerr's behaviour. 'The panel noted that it is a reasonable expectation of everyone working in a public environment, such as a shop, that they will not be approached and given personal, clinical advice and that such advice would normally only be given during a private clinical appointment or at an antenatal class,' they said. 'Therefore, by approaching Patient A in her place of work, outside a clinical relationship, unsolicited, Ms Kerr placed her at significant risk of harm.' The panel found Ms Kerr's fitness to practise was still impaired and that there was a risk of the individual repeating her behaviour. Ms Kerr did not show any remorse for her misconduct or demonstrate any insight into her previous actions, and had not engaged with the NMC since June 2022, the panel said. It made an order to strike Ms Kerr's name from the register, after a 12-month suspension order had previously been imposed last year.
Telegraph
an hour ago
- Telegraph
Time to face the harsh realities of spending orthodoxy
Labour came to power fatuously parroting the word 'change' and yet has shown itself to be the same old tax and spending party it has always been. What it meant was a change of party in office not a change of direction. Not only have taxes gone up but so-called protected spending is set to rise despite record debt levels. Yet if ever a public policy has been tested to destruction surely it is the notion that the NHS will improve if only more money is thrown at it. Even Sir Keir Starmer and Wes Streeting, the Health Secretary, are on record as saying that higher health spending is not the answer to the endemic flaws in the health service and yet another £30 billion is to be announced for the next three years on top of the £22 billion handed over after last year's general election, much of which went on pay and showed nothing in the way of productivity improvement. No mainstream politician is prepared to acknowledge that the problem with the NHS is the fact it is a nationalised industry with all the inherent inefficiencies associated with such. Most other advanced economies in Europe and elsewhere have social insurance systems which work better. But the insistence in Britain of cleaving to the 1948 'founding principle' that treatment should be free at the point of delivery has become a quasi-religious doctrine that few dare challenge. Only Nigel Farage has questioned the wisdom of continuing with a system that patently fails to achieve what others manage to do but has been noticeably quiet on the subject recently because Labour will exploit it mercilessly to see off the Reform threat. Telling people that they will have to pay for something they have always had for free is even more difficult when political parties are prepared to see the health system get worse rather than reform it. The same is true of welfare. Taking benefits from people, even when they are payments introduced just a few years ago like the winter fuel allowance, is hard if the reasons are not explained and the issue is 'weaponised' by opponents. Yet unless the welfare budget is brought under control it will bankrupt the country. If change is to mean anything then we need politicians finally to understand the extent of the country's difficulties and make decisions accordingly. Will we see that from the Chancellor on Wednesday?
South Wales Guardian
2 hours ago
- South Wales Guardian
Midwife struck off after claiming vaccines ‘attacked babies' on social media
Seana Mary Kerr, of Newry, Northern Ireland, also told a pregnant woman in a shop that she should not be wearing a face mask during the Covid-19 pandemic, according to a Nursing and Midwifery Council (NMC) tribunal panel judgment. Ms Kerr, who had been a registered midwife since 2007, was found by a panel to have placed the woman at 'significant risk of harm' with her views, while she had 'risked seriously undermining the public confidence' in her profession at a crucial time with her posts. In the first of three social media posts in September 2020, Ms Kerr said that babies were being attacked in the womb through vaccination of mothers during pregnancy. Then, in March 2021, she claimed healthcare professionals were being 'complicit' in the national response to Covid-19, and that the health crisis was 'a Trojan horse intend[ed] to introduce a new era for humanity'. A further post in December that year made reference to how a group of people, described as 'they', had been 'planting the seeds' about Covid-19 over Christmas 2020 by referring to 'some bat in China'. Ms Kerr's advice and social media comments were given when she had identified herself as a midwife and was 'promoting her opinion on matters of clinical importance', the panel found. 'The panel considered that the actions of Ms Kerr took place during an exceptionally unusual time, where the entirety of the NHS was mobilised to protect the public from the international Covid-19 pandemic,' they said. 'Therefore, by expressing the view that other healthcare professionals, who Ms Kerr was working with in the Trust, were acting in ways which may cause harm, a view Ms Kerr held which was against the recognised guidance at the time, Ms Kerr risked seriously undermining the public confidence in the profession. 'It further noted that by making these accusations that Ms Kerr's colleagues may have suffered harm while working in an unprecedented and challenging situation.' The midwife approached the pregnant woman in the shop, which was her place of work, during the other allegation in question in August 2020. She identified herself as a midwife before advising the woman that she should not be wearing the face mask as it reduced the amount of oxygen her baby was receiving. Ms Kerr went on to tell the woman that she should not receive a flu vaccination as this would increase the risk of her baby being stillborn. The panel found the pregnant woman and her family were caused 'significant emotional harm' as a result of Ms Kerr's behaviour. 'The panel noted that it is a reasonable expectation of everyone working in a public environment, such as a shop, that they will not be approached and given personal, clinical advice and that such advice would normally only be given during a private clinical appointment or at an antenatal class,' they said. 'Therefore, by approaching Patient A in her place of work, outside a clinical relationship, unsolicited, Ms Kerr placed her at significant risk of harm.' The panel found Ms Kerr's fitness to practise was still impaired and that there was a risk of the individual repeating her behaviour. Ms Kerr did not show any remorse for her misconduct or demonstrate any insight into her previous actions, and had not engaged with the NMC since June 2022, the panel said. It made an order to strike Ms Kerr's name from the register, after a 12-month suspension order had previously been imposed last year.
